Caricamento...
Use of Fingolimod in the Management of Relapsing–Remitting Multiple Sclerosis: Experience from Latin America
Once-daily fingolimod 0.5 mg (FTY720; Gilenya(®), Novartis Pharma AG, Basel, Switzerland) is a sphingosine 1-phosphate receptor modulator that is approved for the treatment of relapsing multiple sclerosis (MS); currently, this includes approval in 13 Latin American countries. However, despite a well...
Salvato in:
| Pubblicato in: | Adv Ther |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Springer Healthcare
2015
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4522024/ https://ncbi.nlm.nih.gov/pubmed/26170106 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-015-0226-0 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|